SUMMARY Infarct, perfusion and blood pool scintigraphy were performed in 62 patients during hospitalization for acute myocardial infarction. The largest measured infarct or perfusion image defect and left ventricular ejection fraction were related to the late prognosis determined a mean of 16 months after the event.
SUMMARY Infarct, perfusion and blood pool scintigraphy were performed in 62 patients during hospitalization for acute myocardial infarction. The largest measured infarct or perfusion image defect and left ventricular ejection fraction were related to the late prognosis determined a mean of 16 months after the event.
Breakpoint values for all scintigraphic variables could separate those who were asymptomatic on followup from those who died. The best indicators for selection of survivors and nonsurvivors were a scintigraphic infarct size ¢ 25 cm2 and a perfusion abnormality > 35% of the projected left ventricular area. Among patients with perfusion abnormalities above this limit, 61% died; 93% of those with small perfusion abnormalities survived. Scintigraphic measurements of relative myocardial perfusion and function best separated patients asymptomatic on follow-up from those who developed heart failure and also best identified those with an unfavorable evolution, who developed heart failure or died. Early scintigraphic parameters appeared more accurate than other clinical laboratory indicators for determining late prognosis and could be important in planning treatment after acute infarction.
ACUTE myocardial infarct (AMI) size is an indicator of prognosis after infarction. Postmortem studies have documented that death during the acute phase is frequently associated with infarcts that involve more than 40% of the left ventricular mass. I The clinical course of patients after AMI has also been related to historical, clinical and admission laboratory data,24 to hemodynamic findings during early hospitalization,5 '6 and to the severity of ventricular arrhythmias during the acute phase.7 I Many of these prognostic indicators are indirectly related to AMI size, and several investigators have shown that left ventricular function, one of the main determinants of morbidity and mortality after AMI,9-11 is related to the extent of myocardial necrosis.'214 Similarly, peak serum levels of enzymes released during AMI have shown a general correlation with prognosis15 16 and enzymatic determinations of infarct size from serial serum creatine kinase (CK) measurements have been proposed as prognostic indicators. 17 A search for simple and accurate indicators of prognosis after AMI has been prompted by the unreliability of clinical findings,18 the invasive nature of hemodynamic measurements, and the lack of reproducibility of enzymatic determinations of infarct size. 19 Recently, technetium-99m pyrophosphate (99mTc-PYP) infarct scintigrams and rest thallium-201 (207T1) myocardial perfusion scintigrams were shown to correlate well with pathologic measurements of acute infarct size in dogs20 21 and in humans. 22, 23 Several investigators have reported promising results using scintigraphic variables as prognostic indicators of AMI. Rigo et al. 24 and Schelbert et al. 1 ' found that a normal scintigraphic left ventricular ejection fraction (LVEF) early after AMI predicted survival. The extent and intensity of the abnormality on infarct scintigraphy have also been correlated with morbidity and mortality after AMI. 25 26 Recently, scintigraphic perfusion defect size measured early in patients in Killip class I and II was shown to be the best predictor of early and late mortality in patients with AMI. 27 In the current study, we sought to determine the value of scintigraphic indicators of infarct size and left ventricular function in predicting the late clinical course of patients after AMI. For this purpose, a quantitative analysis of 99mTc-PYP infarct scintigrams, 201T1 perfusion scintigrams, and equilibrium gated blood pool scintigrams was performed during the initial hospitalization in a population of patients admitted with AMI and was correlated with the clinical course of patients during follow-up after hospital discharge.
Methods

Patients
Historical features, including the presence of prior infarction, and electrocardiographic, enzymatic and scintigraphic studies, were evaluated in 62 patients admitted to the coronary care unit with AMI. Fifty-one (82.3%) were males, mean age 69 years (range 52-81 years). Myocardial infarct scintigraphy (99mTc-PYP) was never performed earlier than 1 day or later than 7 days after the onset of symptoms; 55 of 57 studies were performed within 4 days of admission. For each study, 15-20 mCi of 99mTc-PYP manufactured according to the method of Huberty and co-workers32 were administered intravenously and images obtained 2-4 hours later to 300,000 counts in 300 right anterior oblique (RAO), anterior, 450 left anterior oblique (LAO), 60°L AO, and left lateral projections, using a portable Ohio Nuclear series 120 or Searle PhoGamma V scintillation camera with a high-resolution collimator. Focal myocardial abnormalities of intensity grade 2-4 + according to the method of Parkey and co-workers33 were considered abnormal. The absolute area of abnormal 99mTc-PYP uptake was quantitated by planimetry of the Polaroid photographs in the projection that showed the largest abnormality in each patient. Planimetered areas were expressed in square centimeters by using a conversion factor derived from the ratio between the projected and actual areas of the fields of view.
Myocardial perfusion scintigraphy was performed on the day of the onset of symptoms in 21 . patients (44%), in nine within the initial 12 hours. Thallium scintigraphy was performed within 2-4 days after the onset of the acute event in 17 patients (35%) and between the fifth and tenth day in 10 patients (21%).
In each patient, 2 mCi of 207T1 were administered intravenously and scintigraphy was performed 10 minutes later, at rest, using the same scintillation cameras, a low-energy, all-purpose collimator during the initial 20 studies and a high-sensitivity collimator in the remainder. Imaging was performed in each case in the same multiple projections as previously noted where the initial perfusion scintigram was acquired to 300,000 counts and each subsequent projection obtained to isotime. As with quantitation of the infarct scintigram, perfusion abnormalities were quantitated from Polaroid images in the projection showing the largest perfusion abnormality. All Polaroid images were obtained in a standardized manner using 087 film and Vari Back II triple-lens camera, which permits the simultaneous acquisition of three images with varying exposure settings. Associated with the proper display scope intensity, this camera virtually assures the recording of a satisfactory and, in most instances, optimally contrasted image. The variable aperture of the triple-lens camera is adjusted to permit image acquisition with f/8, f/11 and f/16, allowing the camera to cover the large count density sometimes encountered.
A neutral-density filter, coded on each lens and matched to the light predicted by the phosphor of the display scope, enhances the optimal capability of the camera and assures a uniformity of image intensities across the field of view. Scintigraphic areas outlined manually on the original Polaroid image correlated well with areas planimetered using a mechanical hand-held device (r = 0.92). The two measures showed no significant difference by a one-tailed t test from areas measured on images after a uniform fourfold magnification. Similarly, areas manually outlined from the original Polaroid images and mechanically planimetered showed no significant difference from those planimetered using a computerized measurement applied to these same outlines. The mechanical planimeter was calibrated using marked areas of known dimensions.
The reproducibility of the quantitative analysis of infarct and perfusion scintigrams by the methods outlined above were also tested in 20 random patients. When scintigrams were measured blindly twice at least I week apart, the mean absolute intraobserver percentage variation in measurement of the largest projected infarct and perfusion scintigraphic abnormalities were ± 4.2% and + 5.8%, respectively. Expressed similarly, the mean interobserver variation was + 6.5% for infarct scintigrams and ± 7.2% for perfusion scintigrams. When a second blinded observer made the same calculation on both infarct and perfusion scintigrams in all patients, the two observers agreed within + 5% in 85% of cases. With greater disagreement, the measurement was repeated jointly and a consensus value was obtained. Figure 1 shows infarct and perfusion scintigrams and their quantitation in a patient with a small scintigraphic infarct. Figure 2 shows a similar assessment in a patient with a large anterolateral infarction.
Equilibrium blood pool scintigrams were performed on the day of the onset of symptoms in 14 patients (25.5%), 2-4 days thereafter in 34 patients (61.8%), and within 10 days in all patients. In the first 22 patients, 99mTc albumin34 was administered, and in the rest, in vivo labeled red blood cells39 were used. In our first 18 patients, blood pool scintigrams were performed in the dual-gated mode to a total of 800,000 counts acquired in 40-msec end-diastolic and end-systolic frames in 300 RAO and 600 LAO projections. In these studies, LVEF was calculated by the biplane geometric formula of Sandler and Dodge36 applied to the end-diastolic and end-systolic left ventricular perimeter outlines taken from transparencies of the gated images. In the last 40 studies, blood pool scintigraphy was performed using multiple-gated scintigraphy, with the acquisition of 29 frames to a total of 4,500,000 counts in the 300 RAO and "best septal" LAO projections. The latter was performed with a 150 caudal tilt and was chosen from a number of ungated LAO images that best separated the ventricles. All multiplegated studies were acquired on a PDP 11/40 computer and LVEF was calculated by counts data obtained from Five patients died during the initial hospitalization. Fifty-seven patients survived the acute phase and were followed for an average of 16 + 10 months (± SD) (range 10 days to 34 months). Six patients underwent coronary artery bypass graft surgery due to persistent angina 10 days to 14 months after their infarction and were considered to end their follow-up period at that time. Forty-two of the 57 acute survivors were followed after discharge in the cardiac clinic, while the remainder were returned to the care of their referring cardiologist or internist. Patients and their physicians were contacted every 3 months to establish survival and to determine the symptomatic state. Specific interest was taken in the presence of angina, defined as stress-related chest pain, or the equivalent, or CHF.
The latter was indicated by the development of exertional dyspnea, shortness of breath, or easy fatiguability. These findings were always supported by central or peripheral findings on physical examination, including neck vein distention, pulmonary rales, gallop rhythm, evidence of cardiomegaly, hepatomegaly or edema, and by radiographic evidence of pulmonary congestion. Both angina and CHF were assessed according to the criteria of the New York Association. 39 Patients were divided into groups by their status during follow-up. an asymptomatic group (ASX), which included patients who presented no symptoms that required treatment; an angina group (ANG), which included patients who reported only angina and required treatment but showed no evidence of CHF; a CHF group, which included patients who presented symptoms or signs of CHF requiring treatment regardless of the presence or absence of angina; and a group of patients who died of cardiac causes (DCC), which included those who died as a consequence of their infarct during hospitalization as well as those who died during follow-up. Deaths outside the hospital were considered due to cardiac causes if they were recorded as such by the patient's physician, or occurred suddenly (within 6 hours after the onset of symptoms). Among the six patients who underwent coronary artery bypass graft surgery, five were from the ANG and one was from the CHF groups. Seventeen patients (27.4%) died of cardiac causes; they constituted the DCC group. Five of these patients died during the initial hospitalization and 12 after discharge, 11 of them within the first year after their AMI. Twenty-one patients (33.9%) constituted the ASX group and were asymptomatic at the time of discharge, remaining so during the follow-up period, which lasted a mean of 16.4 ± 9.6 months. Twentyfour patients (38.7%) presented cardiac symptoms after discharge: 10 (16.1%), the ANG group, developed angina during the mean follow-up period of 10 (± 10.3 months) and 14 (22.6%), the CHF group, developed CHF during the mean follow-up period of 18.2 + 9.5 months. The duration of the follow-up periods in the ASX, ANG and CHF groups were not statistically different. Table 1 presents the predictive accuracy related to the presence or absence of a variety of clinical variables noted at the time of admission. Although transmural infarction and anterior location were related to a somewhat higher incidence of CHF and death on follow-up (51% and 56%, respectively) than subendocardial infarction and inferior location, these bore no significant relationship to the late clinical outcome. 
Scintigraphic Parameters of Infarct Size
Forty-eight of the 57 (82.5%) 99mTc-PYP studies were positive. Four of 12 patients (33%) with subendocardial infarcts had negative 9mTc-PYP scintigrams and five of 45 (11%) with transmural infarcts had negative scintigrams, imaged a mean of 2.3 days after the onset of symptoms. Only one of the 48 perfusion scintigrams was negative. Imaging in this case was performed on the day after the onset of symptoms. Among 13 201Tl perfusion scintigrams performed in patients with prior infarction, 11 (84.6%) demonstrated perfusion abnormalities in regions different from the location of acute necrosis as determined by the ECG. In six of these 11, where preexisting electrocardiographic Q waves were present, the additional perfusion defects corresponded to the area of old infarction.
The average perfusion abnormality in three projections was always at least 10% lower than the largest measured perfusion defect. While the average perfusion scintigraphic abnormality and the largest measured abnormality could differentiate the ASX group from the DCC group, only the largest projected abnormalities could differentiate among survivor prognostic subgroups. Table 2 shows the mean values obtained for quantitative measures of 99mTc-PYP scintigraphic infarct size, scintigraphic perfusion abnormality and LVEF in 22 patients with and 40 patients without prior infarction for each prognostic subgroup. Although more patients with prior infarction had larger scintigraphic abnormalities, there was no significant difference between scintigraphic indicators in patients with and without prior infarction as a whole or between patients with and without prior infarction in each follow-up group. When the acquired scintigraphic studies were analyzed with respect to their time of acquisition after infarction, there were also no significant differences related simply to the time of imaging.
Scintigraphic Parameters and Mortality
Quantitative scintigraphic values were compared in survivors and nonsurvivors and the results are shown in figure 3 and Figure 6 is a comparison of the mean values for each scintigraphic measurement in each of the three followup groups in surviving patients. Average values of perfusion abnormalities could not discriminate among surviving subgroups and thus were no longer evaluated. Quantitative values for both largest measured absolute and percent perfusion abnormalities and LVEF in the ASX group were significantly different from the values in patients of the CHF group, but were not significantly different from the ANG group. However, the absolute perfusion abnormality and LVEF were significantly different in the ANG group compared with the CHF group. The 99mTc-PYP infarct area was not significantly different in any of the groups, al- though the mean value in the ASX group (17.6 ± 2 cm2) was lower than that seen in both the ANG (23.1 ± 9.7 cm2) and the CHF groups (29.7 + 13.9 cm2). nificantly different in asymptomatic and angina patients, both groups were consolidated to evaluate the discriminating power of each indicator for separating surviving patients who did not develop heart failure from the CHF group. Individual values for each measurement are plotted with respect to the presence or absence of CHF in figure 7 . Classification rates were calculated first using the same breakpoint values chosen for the analysis of mortality. Overall correct classification rates were 73.8% for 99mTc-PYP infarct abnormalities 25 cm2, 74.3% for absolute perfusion abnormality 3 (table 4) .
The discriminating power of these same breakpoint values for separating patients who had unfavorable evolution, including those in the DCC and CHF groups, and those who had a favorable evolution, including those in the ASX and ANG groups, is shown in table 5 . All scintigraphic variables had correct classification rates above 69%. The best scintigraphic study for selection of patients into favorable and unfavorable prognostic groups was the absolute size of the scintigraphic perfusion abnormality. Eighty percent of pa- tIncluding one negative study.
Abbreviations: CHF = congestive heart failure; LVEF = left ventricular ejection fraction. 41 42 have used similar planimetric methods to measure scintigraphic abnormalities after infarction and documented their reproducibility. As in prior studies,25' 27 we have shown that infarct and perfusion scintigraphy performed early after AMI provide an excellent profile of late prognosis. While all scintigraphic studies were obtained during the acute hospitalization, unlike the study of Silverman and co-workers,27 scintigraphic studies were often obtained days after the event. While such delay influences scintigraphic infarct size and, particularly, the size of the perfusion abnormality, 42 Silverman and co-workers27 found no relationship between time of perfusion-scintigraphy and defect size. Similarly, Wackers and co-workers22 have shown a correlation between scintigraphic perfusion abnormalities and pathologic infarct size that appeared little influenced by temporal factors. In the current study, there was no significant difference in either the size or the prognostic significance of measured scintigraphic abnormalities performed at varying intervals after the time of acute infarction.
Although patients with transmural and anterior infarction had a slightly poorer prognosis, patient age, sex, and site of acute infarction bore no relationship to the eventual late prognosis. Since 24 where a high LVEF early after infarction was related with great reliability to a favorable outcome but a low LVEF was related to a variable prognosis.
Scintigraphic measurements were less effective in discriminating surviving patients according to their clinical course and found particular difficulty in separating asymptomatic patients from those who developed angina. The size of the scintigraphic 99mTc-PYP infarct abnormality was larger in patients who developed CHF but could not separate these from asymptomatic patients, possibly owing to the relatively small population size. However, scintigraphic measurements of perfusion and function could separate these groups, suggesting that the occurrence of CHF could be related as much to associated ischemic abnormalities as to the size of the infarct itself. Owing to their relationship to both acute and remote infarction, as well as ongoing ischemia, perfusion defects and LVEF may have specific prognostic advantages. While infarct and perfusion scintigrams could discriminate between patients who developed CHF and all other survivors, the best overall separation between surviving patients who developed CHF and those who did not was, not surprisingly, achieved by measurements of ventricular function (table 4 ). An LVEF of S 42% identified only 57. 1% of CHF patients, but when present, was associated with CHF in all cases.
Combinations of scintigraphic variables did not appear to add prognostic value. However, since each scintigraphic study was not performed in every patient, later studies must assess the incremental prognostic accuracy of multiple scintigraphic parameters.
Part of the prognostic value of a large scintigraphic abnormality relates to an expression of the probable vulnerability of the individual patient to subsequent events. It is likely that the extent of scintigraphic abnormality provided some measure of the reserve capability in each patient; and the larger the initial scintigraphic abnormality in the patient without CHF, the more vulnerable the patient to the development of symptoms.
The value of a reliable prognostic indicator for patients who have suffered an AMI lies in the separation of high-risk patients who may benefit from alternative therapy. In this context, patients who are at risk of death or of developing CHF clearly constitute a group apart from patients who will remain asymptomatic or who will develop angina, a favorable evolution. When breakpoint values were applied to the discrimination of patients who had a favorable or an unfavorable evolution, all scintigraphic indicators had a correct classification rate greater than 69% (table 5) .
These results support previous reports indicating the potential prognostic significance of scintigraphic measurements of infarct size25' 27 and related function'0 measured early after the event. While not perfect predictors of prognosis, a variety of scintigraphic measurements appear to have significant late prognostic value and, considering all patients, in this study were superior to all other clinical or laboratory parameters. Although others assessed the density of scintigraphic abnormality as well as its area,25 27current results were determined by a simple area measurement made by visual assessment of analogue images. Although such measurements are somewhat subjective and susceptible to variations related to photographic technique, they demonstrated satisfactory reproducibility by trained observers. Other methods of evaluation using objective computer assessment might add to scintigraphic accuracy. Scintigraphic determinations are safe, noninvasive, relatively inexpensive and can provide usefui information with a single determination. 
